Jon Congleton
Chief Executive Officer at MINERALYS THERAPEUTICS, INC.
Net worth: 19 M $ as of 2024-03-30
Profile
Jon Congleton is currently the Chief Executive Officer & Director at Mineralys Therapeutics, Inc. and an Operating Partner at Catalys Pacific LLC.
Previously, he served as the President & Chief Executive Officer at Alpine Immune Sciences, Inc. and the President, Chief Executive Officer & Director at Ipi Legacy Liquidation Co. He also held the position of President, Chief Executive Officer & Director at Nivalis Therapeutics, Inc. from 2014 to 2017.
Prior to that, he worked as the Senior VP-Global Brand Strategic Marketing at Teva Pharmaceutical Industries Ltd.
and as the Vice President & General Manager at Teva Neuroscience, Inc. Mr. Congleton completed his undergraduate degree at Kansas State University.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2024-03-14 | 1,454,235 ( 2.93% ) | 19 M $ | 2024-03-30 |
Jon Congleton active positions
| Companies | Position | Start |
|---|---|---|
| MINERALYS THERAPEUTICS, INC. | Chief Executive Officer | 2020-10-31 |
Catalys Pacific LLC
 Catalys Pacific LLC Investment ManagersFinance Catalys Pacific LLC (Catalys Pacific) is a venture capital firm founded in 2018 by BT Slingsby. The firm is headquartered in Cayman Islands. | Private Equity Investor | - |
Former positions of Jon Congleton
| Companies | Position | End |
|---|---|---|
| IPI LEGACY LIQUIDATION CO | Chief Executive Officer | 2020-05-04 |
Nivalis Therapeutics, Inc.
 Nivalis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Nivalis Therapeutics, Inc. is a clinical stage pharmaceutical company, which engages in discovery, development, and commercialization of product for patients with cystic fibrosis. Its product includes N91115, a small molecule that addresses a defect in the cystic fibrosis transmembrane conductance regulator. The company was founded in 2008 and is headquartered in Boulder, CO. | Chief Executive Officer | 2017-01-14 |
| ALPINE IMMUNE SCIENCES, INC. | Chief Executive Officer | 2016-12-31 |
| TEVA PHARMACEUTICAL INDUSTRIES LIMITED | Sales & Marketing | - |
Teva Neuroscience, Inc.
 Teva Neuroscience, Inc. Pharmaceuticals: MajorHealth Technology Teva Neuroscience, Inc. developed and marketed drugs for neurological disorders. The company's product COPAXONE was used to reduce relapses caused by relapsing-remitting multiple sclerosis. It also offered treatment for Parkinson's disease. Teva Neuroscience was founded in 1997 and was located in Kansas City, MO | Corporate Officer/Principal | - |
Training of Jon Congleton
| Kansas State University | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 4 |
|---|---|
| TEVA PHARMACEUTICAL INDUSTRIES LIMITED | Health Technology |
| IPI LEGACY LIQUIDATION CO | Health Technology |
| ALPINE IMMUNE SCIENCES, INC. | Health Technology |
| MINERALYS THERAPEUTICS, INC. | Health Technology |
| Private companies | 3 |
|---|---|
Teva Neuroscience, Inc.
Teva Neuroscience, Inc. Pharmaceuticals: MajorHealth Technology Teva Neuroscience, Inc. developed and marketed drugs for neurological disorders. The company's product COPAXONE was used to reduce relapses caused by relapsing-remitting multiple sclerosis. It also offered treatment for Parkinson's disease. Teva Neuroscience was founded in 1997 and was located in Kansas City, MO | Health Technology |
Catalys Pacific LLC
Catalys Pacific LLC Investment ManagersFinance Catalys Pacific LLC (Catalys Pacific) is a venture capital firm founded in 2018 by BT Slingsby. The firm is headquartered in Cayman Islands. | Finance |
Nivalis Therapeutics, Inc.
Nivalis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Nivalis Therapeutics, Inc. is a clinical stage pharmaceutical company, which engages in discovery, development, and commercialization of product for patients with cystic fibrosis. Its product includes N91115, a small molecule that addresses a defect in the cystic fibrosis transmembrane conductance regulator. The company was founded in 2008 and is headquartered in Boulder, CO. | Health Technology |
- Stock Market
- Insiders
- Jon Congleton
